
Opinion|Videos|July 10, 2024
Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
Advertisement
Video content above is prompted by the following questions:
- What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
- Discuss the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement